Literature DB >> 24488782

A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia.

Masahiro Ashizawa1, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Miki Sato, Kiriko Terasako, Shun-Ichi Kimura, Misato Kikuchi, Hideki Nakasone, Shinichi Kako, Junya Kanda, Rie Yamazaki, Aki Tanihara, Junji Nishida, Yoshinobu Kanda.   

Abstract

Conditioning regimens consisting of reduced-dose cyclophosphamide (CY) and fludarabine (FDR) have been investigated for use in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with aplastic anemia to reduce the toxicities associated with CY. However, the ideal dose of CY has not been identified. In addition, little information is available regarding donor cell chimerism after allo-HSCT with these regimens. Therefore, we retrospectively analyzed 13 patients who underwent allo-HSCT with half-dose CY (100 mg/kg in total), FDR, and anti-thymocyte globulin at total doses of 2.5-10 mg/kg at our center. All the patients except one, who died due to encephalopathy on day 20, achieved neutrophil engraftment a median of 18.5 days after HSCT with complete donor-type chimerism. Two patients who received a graft from an HLA-matched donor subsequently developed mixed chimerism (MC) associated with transfusion-dependent cytopenia. One became transfusion-independent after donor lymphocyte infusion, but continues to exhibit MC. The other regained complete donor-type chimerism after the cessation of cyclosporine, but remains transfusion-dependent. These findings suggest that a conditioning regimen with half-dose CY and FDR is effective for achieving neutrophil engraftment and complete donor-type chimerism. However, subsequent MC may be observed, especially after HLA-matched HSCT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488782     DOI: 10.1007/s12185-014-1501-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

Authors:  Judith C Marsh; Vikas Gupta; Ziyi Lim; Aloysius Y Ho; Robin M Ireland; Janet Hayden; Victoria Potter; Mickey B Koh; M Serajul Islam; Nigel Russell; David I Marks; Ghulam J Mufti; Antonio Pagliuca
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

Authors:  A Bacigalupo; F Locatelli; E Lanino; J Marsh; G Socié; S Maury; A Prete; A Locasciulli; S Cesaro; J Passweg
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

3.  Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.

Authors:  R Huss; H J Deeg; T Gooley; E Bryant; W Leisenring; R Clift; C D Buckner; P Martin; R Storb; F R Appelbaum
Journal:  Bone Marrow Transplant       Date:  1996-10       Impact factor: 5.483

4.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

Authors:  Jakub Tolar; H Joachim Deeg; Sally Arai; Mitchell Horwitz; Joseph H Antin; John M McCarty; Roberta H Adams; Marian Ewell; Eric S Leifer; Iris D Gersten; Shelly L Carter; Mary M Horowitz; Ryotaro Nakamura; Michael A Pulsipher; Nancy L Difronzo; Dennis L Confer; Mary Eapen; Paolo Anderlini
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-27       Impact factor: 5.742

6.  Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Y Kanda; S Mineishi; T Saito; A Saito; S Yamada; M Ohnishi; A Chizuka; H Niiya; K Suenaga; K Nakai; T Takeuchi; A Makimoto; R Tanosaki; M Kami; Y Tanaka; S Fujita; T Watanabe; Y Kobayashi; K Tobinai; Y Takaue
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

7.  In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.

Authors:  Yoshinobu Kanda; Kumi Oshima; Shinichi Kako; Takahiro Fukuda; Naoyuki Uchida; Koichi Miyamura; Yukio Kondo; Shinji Nakao; Koji Nagafuji; Toshihiro Miyamoto; Mineo Kurokawa; Yasushi Okoshi; Shigeru Chiba; Yasuo Ohashi; Yoichi Takaue; Shuichi Taniguchi
Journal:  Am J Hematol       Date:  2013-02-28       Impact factor: 10.047

8.  Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.

Authors:  B George; V Mathews; A Viswabandya; M L Kavitha; A Srivastava; M Chandy
Journal:  Bone Marrow Transplant       Date:  2007-04-23       Impact factor: 5.483

9.  Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease.

Authors:  R S Hill; F B Petersen; R Storb; F R Appelbaum; K Doney; S Dahlberg; R Ramberg; E D Thomas
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

10.  Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.

Authors:  Sébastien Maury; Andrea Bacigalupo; Paolo Anderlini; Mahmoud Aljurf; Judith Marsh; Gérard Socié; Rosi Oneto; Jakob R Passweg
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

View more
  2 in total

1.  Reduced-dose cyclophosphamide in combination with fludarabine and anti-thymocyte globulin as a conditioning regimen for allogeneic hematopoietic stem cell transplantation for aplastic anemia.

Authors:  Sumiko Kohashi; Takehiko Mori; Risa Hashida; Jun Kato; Masuho Saburi; Taku Kikuchi; Yuya Koda; Takaaki Toyama; Yusuke Yamane; Satomi Yamanaka; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2014-11-09       Impact factor: 2.490

2.  [Therapeutic effect of CY-fTBI and BMM conditioning regimen in the process of allo-HSCT treating Ⅲ,Ⅳ non-Hodgkin lymphoma: 15 years analysis of single-center].

Authors:  Ting Sun; Liangding Hu; Min Jiang; Hongmei Ning; Bin Zhang; Jing Ren; Yuhang Li; Botao Li; Jianlin Chen; Fan Yang; Chen Xu; Jun Wang; Xiao Lou; Jiangwei Hu; Hu Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.